Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.
James J. Hsieh(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Nancy Bouvier(University of California, San Francisco), Patrizia Pinciroli(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci, Patricia Wang(Cornell University), Michael Chevinsky(Barnes-Jewish Hospital), Jennifer J. Knox(National Cancer Center), Maurizio Voi(Curis (United States)), Kety Huberman, Umesh Bhanot(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), William Lee(Drexel University), Parul Patel(Novartis (United States)), Emily H. Cheng(University of Wisconsin–Madison), David Chen(Novartis (United States)), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Mahtab Marker(Novartis (United States)), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center)
Cited by 26
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k